# A Safety Study of 212Pb-Pentixather Radioligand Therapy

> **NCT05557708** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Yusuf Menda** · enrollment: 20 (estimated)

## Conditions studied

- Carcinoid Tumor Lung
- Neuroendocrine Tumor of the Lung
- Carcinoma, Small-Cell Lung

## Interventions

- **DRUG:** 212-Lead Pentixather
- **DIAGNOSTIC_TEST:** 203-Lead Pentixather SPECT/CT

## Key facts

- **NCT ID:** NCT05557708
- **Lead sponsor:** Yusuf Menda
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557708, "A Safety Study of 212Pb-Pentixather Radioligand Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05557708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*